CN103432166A - 一种痰瘀互结型卵巢囊肿动物模型的制备方法 - Google Patents
一种痰瘀互结型卵巢囊肿动物模型的制备方法 Download PDFInfo
- Publication number
- CN103432166A CN103432166A CN2013103772659A CN201310377265A CN103432166A CN 103432166 A CN103432166 A CN 103432166A CN 2013103772659 A CN2013103772659 A CN 2013103772659A CN 201310377265 A CN201310377265 A CN 201310377265A CN 103432166 A CN103432166 A CN 103432166A
- Authority
- CN
- China
- Prior art keywords
- ovarian cyst
- animal model
- preparation
- type ovarian
- blood stasis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 208000025661 ovarian cyst Diseases 0.000 title claims abstract description 41
- 206010062717 Increased upper airway secretion Diseases 0.000 title claims abstract description 33
- 208000026435 phlegm Diseases 0.000 title claims abstract description 33
- 238000010171 animal model Methods 0.000 title claims abstract description 24
- 238000002360 preparation method Methods 0.000 title claims abstract description 14
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims abstract description 18
- UYIFTLBWAOGQBI-BZDYCCQFSA-N Benzhormovarine Chemical compound C([C@@H]1[C@@H](C2=CC=3)CC[C@]4([C@H]1CC[C@@H]4O)C)CC2=CC=3OC(=O)C1=CC=CC=C1 UYIFTLBWAOGQBI-BZDYCCQFSA-N 0.000 claims abstract description 16
- 229950002007 estradiol benzoate Drugs 0.000 claims abstract description 16
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims abstract description 14
- 239000000243 solution Substances 0.000 claims abstract description 12
- 235000012000 cholesterol Nutrition 0.000 claims abstract description 7
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims abstract description 7
- 229920000053 polysorbate 80 Polymers 0.000 claims abstract description 7
- NRHMKIHPTBHXPF-TUJRSCDTSA-M sodium cholate Chemical compound [Na+].C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 NRHMKIHPTBHXPF-TUJRSCDTSA-M 0.000 claims abstract description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 6
- 239000002994 raw material Substances 0.000 claims abstract description 5
- 230000012173 estrus Effects 0.000 claims abstract description 4
- 230000003203 everyday effect Effects 0.000 claims abstract description 4
- 238000010254 subcutaneous injection Methods 0.000 claims abstract description 4
- 239000007929 subcutaneous injection Substances 0.000 claims abstract description 4
- 210000004369 blood Anatomy 0.000 claims description 37
- 239000008280 blood Substances 0.000 claims description 37
- 238000000034 method Methods 0.000 claims description 13
- 239000003814 drug Substances 0.000 claims description 11
- 239000010775 animal oil Substances 0.000 claims description 9
- 210000000481 breast Anatomy 0.000 claims description 6
- 238000003304 gavage Methods 0.000 claims description 6
- 241000282894 Sus scrofa domesticus Species 0.000 claims description 4
- 229940000406 drug candidate Drugs 0.000 claims description 4
- 238000012216 screening Methods 0.000 claims description 4
- 238000011156 evaluation Methods 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims description 2
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 abstract description 7
- 229960005309 estradiol Drugs 0.000 abstract description 7
- 229930182833 estradiol Natural products 0.000 abstract description 7
- 235000013336 milk Nutrition 0.000 abstract 3
- 239000008267 milk Substances 0.000 abstract 3
- 210000004080 milk Anatomy 0.000 abstract 3
- 235000019737 Animal fat Nutrition 0.000 abstract 1
- 210000001672 ovary Anatomy 0.000 description 19
- 238000012360 testing method Methods 0.000 description 9
- 108010023302 HDL Cholesterol Proteins 0.000 description 4
- 108010028554 LDL Cholesterol Proteins 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 238000004043 dyeing Methods 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 4
- 210000003969 blast cell Anatomy 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 230000008034 disappearance Effects 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 239000004006 olive oil Substances 0.000 description 3
- 235000008390 olive oil Nutrition 0.000 description 3
- 231100000915 pathological change Toxicity 0.000 description 3
- 230000036285 pathological change Effects 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 2
- 210000001015 abdomen Anatomy 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 210000002570 interstitial cell Anatomy 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 206010051283 Fluid imbalance Diseases 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- 206010061245 Internal injury Diseases 0.000 description 1
- 230000004520 agglutination Effects 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000008451 emotion Effects 0.000 description 1
- 238000000802 evaporation-induced self-assembly Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000556 factor analysis Methods 0.000 description 1
- 210000003191 femoral vein Anatomy 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 230000003397 luteinic effect Effects 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000003821 menstrual periods Effects 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000000287 oocyte Anatomy 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 208000015124 ovarian disease Diseases 0.000 description 1
- 201000004535 ovarian dysfunction Diseases 0.000 description 1
- 210000002394 ovarian follicle Anatomy 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 210000003684 theca cell Anatomy 0.000 description 1
- 229940126680 traditional chinese medicines Drugs 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
- A61K49/0008—Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2207/00—Modified animals
- A01K2207/20—Animals treated with compounds which are neither proteins nor nucleic acids
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/035—Animal model for multifactorial diseases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Environmental Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Zoology (AREA)
- Endocrinology (AREA)
- Toxicology (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Animal Husbandry (AREA)
- Gastroenterology & Hepatology (AREA)
- Pathology (AREA)
- Rheumatology (AREA)
- Biodiversity & Conservation Biology (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明公开了一种痰瘀互结型卵巢囊肿动物模型的制备方法,包括如下步骤:(1)将苯甲酸雌二醇溶液施用于发情期大鼠,施用剂量为1.5ml/100g,每5天施用一次,连续4次,所述苯甲酸雌二醇溶液的浓度为3.75mg/ml;(2)从第一次施用苯甲酸雌二醇溶液当天开始,灌胃1ml/100g的高脂乳,每天灌胃一次,连续20次,所述高脂乳每100ml包含如下重量配比的原料:胆固醇20g、胆酸钠3g、动物油脂35g、丙二醇20ml、吐温-8010ml,其余为水。本发明采用皮下注射雌二醇与灌胃高脂乳联合造模的方式,成功地诱导痰瘀互结型卵巢囊肿动物模型,应用前景良好。
Description
技术领域
本发明涉及一种痰瘀互结型卵巢囊肿动物模型的制备方法。
背景技术
卵巢囊肿(ovarian cysts,OC)指卵巢内部或表面生成肿块,肿块内的物质通常是液体,有时也可能是固体,或是液体与固体的混合。卵巢囊肿是最常见的妇科疾病,可发生于任何女性年龄,尤其多发于育龄期妇女。卵巢囊肿的发病机制有多个方面,主要是下丘脑-垂体-卵巢功能紊乱导致病理性地促性腺激素分泌,影响卵泡的产生、发育、释放等环节,最终形成卵巢囊肿。卵巢囊肿在中医属于“积聚”、“症瘕”和“肠覃”的范畴,其形成多因经期或产后六淫外邪入侵,七情损伤,房事不慎及饮食劳倦,以致正气虚弱,气血津液失调,久则脏腑失和,气滞血瘀,血脉受阻,痰湿凝结,久积成为卵巢囊肿。
痰淤互结型卵巢囊肿主要表现是卵巢病变,血脂升高,血流变各指标升高,并伴有雌二醇含量的增多,中医认为痰淤互结型卵巢囊肿主由外感湿热之邪以及情志内伤,致气滞、痰饮、淤血停滞郁久化热而致。当今社会,生活节奏快,生活习惯不规律,心理压力大,造成卵巢囊肿发病率高,因此,开发新型痰淤互结型卵巢囊肿药物具有重要的临床意义和社会价值。
目前,未见痰淤互结型卵巢囊肿的动物模型,难以有效进行新药筛选。
发明内容
为了解决上述问题,本发明提供了一种痰瘀互结型卵巢囊肿动物模型的制备方法。
本发明痰瘀互结型卵巢囊肿动物模型的制备方法,包括如下步骤:
(1)将苯甲酸雌二醇溶液施用于发情期大鼠,施用剂量为1.5ml/100g,每5天施用一次,连续4次,所述苯甲酸雌二醇溶液的浓度为3.75mg/ml;
(2)从第一次施用苯甲酸雌二醇溶液当天起,灌胃1ml/100g的高脂乳,每天灌胃一次,连续20次,所述高脂乳每100ml包含如下重量配比的原料:胆固醇20g、胆酸钠3g、动物油脂35g、丙二醇20ml、吐温-8010ml,其余为水。
步骤(1)中,所述的施用方式是皮下注射。
步骤(2)中,所述动物油脂是猪油。
本发明还提供了一种建立痰瘀互结型卵巢囊肿动物模型的组合物,每100ml包含如下重量配比的原料:胆固醇20g、胆酸钠3g、动物油脂35g、丙二醇20ml、吐温-8010ml,其余为水。
所述动物油脂是猪油。
本发明还提供了前述动物模型在筛选治疗痰瘀互结型卵巢囊肿的药物中的用途。
本发明还提供了筛选治疗痰瘀互结型卵巢囊肿药物的方法,它包括如下步骤:
a、按照前述方法,建立痰瘀互结型卵巢囊肿动物模型;
b、将候选药物施用于动物模型;
c、用动物模型评价潜在的治疗痰瘀互结型卵巢囊肿的药物。
本发明造模方法可以诱导大鼠卵巢病变,血脂升高、血流变各指标升高,并伴有雌二醇含量的增多,出现痰淤互结型卵巢囊肿的临床表现,成功地建立了痰瘀互结型卵巢囊肿动物模型,并且,给药方法简单,可重复性强。
显然,根据本发明的上述内容,按照本领域的普通技术知识和惯用手段,在不脱离本发明上述基本技术思想前提下,还可以做出其它多种形式的修改、替换或变更。
以下通过实施例形式的具体实施方式,对本发明的上述内容再作进一步的详细说明。但不应将此理解为本发明上述主题的范围仅限于以下的实例。凡基于本发明上述内容所实现的技术均属于本发明的范围。
附图说明
图1空白组卵巢HE染色×4;
图2模型组卵巢HE染色×4,A—卵泡内卵母细胞缺失;
图3模型组卵巢HE染色×4,A—卵泡内卵母细胞缺失,颗粒细胞层减少;B—完全黄体化的卵泡;C—有卵母细胞的卵泡。
具体实施方式
实施例1本发明痰瘀互结型卵巢囊肿动物模型的建立方法
1材料与方法
1.1实验动物
健康SD清洁雌性未孕大鼠,体重150±10g。由四川大学实验动物中心提供(动物合格证号:SCXK川2008-24),适应性喂养1周后备用。
1.2主要试剂
苯甲酸雌二醇注射液,苯甲酸雌二醇的浓度为5mg/ml(天津金耀氨基酸有限公司,国药准字H12020529);橄榄油(成都市科龙化工制剂厂);胆固醇(上海伯奥生物科技有限公司);药用吐温-80(南京威尔化工有限公司);快速改良巴氏染液(南京建成科技有限公司);雌二醇EISA试剂盒(上海晶研生物科技有限公司);总胆固醇(CHO)试剂盒、甘油三酯(TG)试剂盒、低密度脂蛋白胆固醇(LDL-C)试剂盒及高密度脂蛋白胆固醇(HDL-C)试剂盒,均由北京北化康泰临床试剂有限公司提供。
1.3主要仪器
切片机(Leica有限公司);ZPJ-1展片机(天津天利航空机有限公司);101-2A型电热鼓风干燥箱(天津市泰斯特仪器有限公司);Biotek酶标仪(Gene Company有限公司);D系列全自动生化仪(Sinnowa有限公司);BX41正置荧光显微镜(Olympus有限公司)。
1.4实验方法
取胆固醇20g、胆酸钠3g、动物油脂35g、丙二醇20ml、吐温-8010ml,加蒸馏水至100ml,混匀,配制成为高脂乳,备用。
用橄榄油稀释苯甲酸雌二醇注射液,苯甲酸雌二醇注射液与橄榄油的比例为3:1(v/v),得浓度为3.75mg/ml的苯甲酸雌二醇溶液,备用。
将SD大鼠按照体重随机分成空白对照组和模型组,每组10只。空白对照组不做处理。模型组:在大鼠的发情期,皮下注射苯甲酸雌二醇溶液,注射剂量为1.5ml/100g,在第5天,10天,15天时各加注1次;从第1次注射苯甲酸雌二醇溶液当天开始,每天按大鼠体重灌胃高脂乳,灌胃剂量为1ml/100g,总共造模20天。
造模给药第20天,股静脉取全血3ml检测血流变学,另取3ml离心得血清用试剂盒采用D系列全自动生化仪测定CHO、TG、LDL-C、HDL-C;取血清E2试剂盒采用Biotek酶标仪测定E2含量;剖取双侧卵巢称重并计算脏器系数,用排水法测定体积;取左侧卵巢,匀浆,离心取上清,用E2试剂盒采用Biotek酶标仪测定E2含量;留存右侧卵巢,固定、脱水、石腊包埋、切片、HE染色观察卵巢组织病理学变化。
1.5统计学方法
采用SPSS13.0统计软件包进行分析,正态分布计量资料数据以均数±标准差(x±s)表示。各组间采用单因素方差分析,检验标准以P<0.05为有显著性差异,P<0.01及P<0.001为有极显著性差异。
2结果
2.1卵巢组织HE染色结果
如图1所示,空白组卵巢内见各期发育阶段的卵泡,未见明显病变。
如图2~3所示,模型组卵巢多出现典型的卵巢囊肿病变特征:较多早期发育的小卵泡和闭锁卵泡,囊状扩张卵泡明显增加,各种发育阶段卵泡减少,颗粒细胞层减少至2-3层,一些大的囊状卵泡几乎没有颗粒细胞,卵泡膜增厚;卵泡内卵母细胞缺失,放射冠消失;间质细胞明显增生,很多外覆卵泡的卵泡内膜黄素化,卵巢间质有时可见黄素化间质细胞。
2.2卵巢脏器系数
卵巢脏器系数和卵巢体积的检测结果见下表1:
注:与空白组比较,**P<0.01,***P<0.001.
与空白组比较,模型组卵巢脏器系数明显升高,体积也明显增大,差异极显著,说明模型组卵巢出现病变(P<0.01,P<0.001)。
2.3血液流变学
结果见下表2:
注:与空白组比较,*P<05,**P<0.01,***P<0.001.
与空白对照组比较,模型组全血黏度及红细胞凝集指数均有明显升高,有显著性或极显著性差异,说明模型组的血液流变学指数升高,血液流动性降低,粘滞性、凝固性增强(P<0.05,P<0.01,P<0.001)。
2.4血脂指标
结果见下表3:
注:*与空白组比较,*P<0.05,**P<0.01.
与空白对照组比较,模型组大鼠HDL-C、LDL-C、CHO及TG水平明显升高,差异有显著性或极显著性差异,说明模型组的血脂显著升高(P<0.05或P<0.01)。
2.5雌二醇含量
结果见下表4:
注:与空白组比较,***P<0.001.
与空白对照组比较,模型组卵巢及血清中雌二醇含量明显增高,且差异有显著性或极显著性差异(P<0.05,P<0.01或P<0.001)。
综上,本发明方法造成大鼠出现典型的卵巢囊肿病变特征,血液流变学指数升高、血脂升高、雌二醇含量增加,出现了痰淤互结型卵巢囊肿的临床表现,成功建立了痰淤互结型卵巢囊肿动物模型。
实施例2用本发明模型筛选治疗痰淤互结型卵巢囊肿的药物
a、按照实施例1方法建立的痰淤互结型卵巢囊肿;
b、将候选药物施用于动物模型;
c、观察候选药物对痰淤互结型卵巢囊肿的各种指标的影响情况,评价潜在的治疗痰淤互结型卵巢囊肿的药物。
Claims (7)
1.一种痰瘀互结型卵巢囊肿动物模型的制备方法,其特征在于:包括如下步骤:
(1)将苯甲酸雌二醇溶液施用于发情期大鼠,施用剂量为1.5ml/100g,每5天施用一次,连续4次,所述苯甲酸雌二醇溶液的浓度为3.75mg/ml;
(2)从第一次施用苯甲酸雌二醇溶液当天开始,灌胃1ml/100g的高脂乳,每天灌胃一次,连续20次,所述高脂乳每100ml包含如下重量配比的原料:胆固醇20g、胆酸钠3g、动物油脂35g、丙二醇20ml、吐温-8010ml,其余为水。
2.根据权利要求1所述的制备方法,其特征在于:步骤(1)中,所述的施用方式是皮下注射。
3.根据权利要求1所述的制备方法,其特征在于:步骤(2)中,所述动物油脂是猪油。
4.一种建立痰瘀互结型卵巢囊肿动物模型的组合物,其特征在于:每100ml包含如下重量配比的原料:胆固醇20g、胆酸钠3g、动物油脂35g、丙二醇20ml、吐温-8010ml,其余为水。
5.根据权利要求4所述的饲料,其特征在于:所述动物油脂是猪油。
6.权利要求1~3任意一项所述方法制备的动物模型在筛选治疗痰瘀互结型卵巢囊肿的药物中的用途。
7.一种筛选治疗痰瘀互结型卵巢囊肿的药物的方法,其特征在于:它包括如下步骤:
a、按照权利要求1~3任意一项所述方法,建立痰瘀互结型卵巢囊肿动物模型;
b、将候选药物施用于动物模型;
c、用动物模型评价潜在的治疗痰瘀互结型卵巢囊肿的药物。
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310377265.9A CN103432166B (zh) | 2013-08-26 | 2013-08-26 | 一种痰瘀互结型卵巢囊肿动物模型的制备方法 |
PCT/CN2013/084043 WO2015027539A1 (zh) | 2013-08-26 | 2013-09-24 | 一种痰瘀互结型卵巢囊肿动物模型的制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310377265.9A CN103432166B (zh) | 2013-08-26 | 2013-08-26 | 一种痰瘀互结型卵巢囊肿动物模型的制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN103432166A true CN103432166A (zh) | 2013-12-11 |
CN103432166B CN103432166B (zh) | 2016-03-16 |
Family
ID=49685952
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201310377265.9A Expired - Fee Related CN103432166B (zh) | 2013-08-26 | 2013-08-26 | 一种痰瘀互结型卵巢囊肿动物模型的制备方法 |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN103432166B (zh) |
WO (1) | WO2015027539A1 (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2722988C1 (ru) * | 2019-11-19 | 2020-06-05 | федеральное государственное бюджетное образовательное учреждение высшего образования "Башкирский государственный медицинский университет" Министерства здравоохранения Российской Федерации | Способ моделирования проканцерогенного действия фулвестранта на яичники потомства женского пола у лабораторных мышей |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102698292A (zh) * | 2011-05-24 | 2012-10-03 | 唐和斌 | 一种模拟人盆腔炎动物模型的制作方法 |
-
2013
- 2013-08-26 CN CN201310377265.9A patent/CN103432166B/zh not_active Expired - Fee Related
- 2013-09-24 WO PCT/CN2013/084043 patent/WO2015027539A1/zh active Application Filing
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102698292A (zh) * | 2011-05-24 | 2012-10-03 | 唐和斌 | 一种模拟人盆腔炎动物模型的制作方法 |
Non-Patent Citations (2)
Title |
---|
孙声桃等: "症瘕康治疗卵巢囊肿的实验研究", 《河南医药信息》, vol. 10, no. 8, 30 April 2002 (2002-04-30), pages 8 - 9 * |
贾海荣等: "温经消症丸对卵巢囊肿大鼠卵巢囊肿的治疗作用研究", 《陕西中医》, vol. 29, no. 9, 30 September 2008 (2008-09-30), pages 1242 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2722988C1 (ru) * | 2019-11-19 | 2020-06-05 | федеральное государственное бюджетное образовательное учреждение высшего образования "Башкирский государственный медицинский университет" Министерства здравоохранения Российской Федерации | Способ моделирования проканцерогенного действия фулвестранта на яичники потомства женского пола у лабораторных мышей |
Also Published As
Publication number | Publication date |
---|---|
CN103432166B (zh) | 2016-03-16 |
WO2015027539A1 (zh) | 2015-03-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Ahmed et al. | Ovarian cancer stem cells: Molecular concepts and relevance as therapeutic targets | |
CN105194550B (zh) | 一种中药复方组合物及其在抗前列腺癌中的应用 | |
Vazquez-Martin et al. | Reprogramming of non-genomic estrogen signaling by the stemness factor SOX2 enhances the tumor-initiating capacity of breast cancer cells | |
Singsuksawat et al. | Increased ETV4 expression correlates with estrogen-enhanced proliferation and invasiveness of cholangiocarcinoma cells | |
Fan et al. | Mechanism of modulation through PI3K-AKT pathway about Nepeta cataria L.’s extract in non-small cell lung cancer | |
CN105219730A (zh) | 卵巢癌癌组织3d培养方法及其在药效评价中的应用 | |
Li et al. | Chinese herbal formulas Miao‐Yi‐Ai‐Tang inhibits the proliferation and migration of lung cancer cells through targeting β‐catenin/AXIN and presents synergistic effect with cisplatin suppressing lung cancer | |
CN103933411B (zh) | 一种治疗脂肪肝的中药组合物及其制备方法和用途 | |
CN103432166B (zh) | 一种痰瘀互结型卵巢囊肿动物模型的制备方法 | |
CN104083368B (zh) | G-1在制备基于g蛋白偶联受体30的三阴性乳腺癌靶向药物方面的应用 | |
CN105395771B (zh) | 一种新温肾生精饮及其制备方法 | |
CN101653438A (zh) | 黄芪中毛蕊异黄酮在制备血管保护、促进血管新生药物中的应用 | |
CN101474256B (zh) | 一种苍耳子鼻炎软胶囊制剂及其制备方法 | |
CN102772806A (zh) | 小分子核酸miR-302用于治疗或预防睾丸癌的用途 | |
Dai et al. | Hederagenin suppresses glioma cell biological activities via Nur77 in vitro study | |
CN106540274B (zh) | 一种miRNA在制备治疗矽肺药物中的应用 | |
CN105560308B (zh) | 金花葵花在制备用于预防和治疗前列腺疾病的产品中的应用 | |
CN103393708B (zh) | 一种治疗心脑血管疾病的人参皂苷、麦冬皂苷d组合物 | |
CN106880784A (zh) | 一种具有缓解疲劳、延缓衰老的中药组合物及其应用 | |
CN102416026B (zh) | 纳米级银杏叶提取物外用制剂的制备方法 | |
CN104096089B (zh) | 一种治疗缺血性中风的中药组合物及其胶囊剂和制法 | |
CN104127617A (zh) | 一种新的药物组合物及其应用 | |
Liang et al. | Combining network pharmacology and experimental validation to study the action and mechanism of water extract of Asparagus against colorectal cancer | |
CN102716424B (zh) | 一种治疗乳癖的药物组合物及其制备方法和用途 | |
Wang et al. | Network and Experimental Pharmacology on Mechanism of Yixintai Regulates the TMAO/PKC/NF-κB Signaling Pathway in Treating Heart Failure |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20160316 Termination date: 20180826 |